Abstract:e23134 Background: Precision oncology promises tailored cancer treatments, yet current methods often overlook individual patient variability. The AI-powered Case Matching Assistant (ACMA) system addresses this by utilizing real-world data (RWD) from over 100,000 clinical cases to personalize treatment strategies, considering genetic profiles, cancer types, treatment stages, and drug interactions. Methods: ACMA enhances the Large Language Model (LLM) with oncology-specific pretraining that encompasses both molecular and clinical data, ensuring a holistic understanding of patient profiles. It employs cosine similarity for multi-faceted case comparisons, integrating genetic, biomarker, and vital clinical information. Context-aware learning prompts fine-tune the LLM, generating recommendations that reflect the full spectrum of patient-specific data, from genetic variations to clinical histories and treatment responses, facilitating truly personalized treatment pathways. Results: Preliminary results show ACMA's tailored recommendations improve patient outcomes, with increased median survival rates and cost-effective treatment options. The system's 90% relevance match for clinical trial enrollment also expands access to novel therapies. In the absence of a standard treatment protocol for BRCA germline mutations in advanced lung cancer, ACMA provides crucial insights. For instance, a 36-year-old female with BRCA1 c.527del mutation achieved complete remission with a PFS of 38 months after a combination therapy trial. A 56-year-old male with a BRCA2 S1722Yfs*mutation saw partial remission and over 6 months PFS with olaparib. Another male patient, a smoker with concurrent BRCA2 G1712X and TP53 mutations, experienced partial remission following apatinib therapy. ACMA analyzed treatment data from similar genetic profiles and identified a targeted therapy that had shown efficacy in comparable cases. The oncologist used this information as a reference to adjust the treatment plan, resulting in a positive clinical outcome for the patient. This example underscores the potential of ACMA to provide actionable insights for personalized cancer care. Conclusions: Surpassing traditional single-feature matching, ACMA rapidly aligns multi-dimensional characteristics such as cancer type, disease stage, molecular data, and treatment phases. It customizes the interplay of these features with medical logic, delivering tailored outputs through the LLM. This approach offers an economical, convenient, and timely solution, setting a new benchmark in personalized oncology and establishing ACMA as a leader in the field. This distinctive advantage not only enhances patient outcomes but also establishes a formidable barrier to entry for competitors, solidifying ACMA's position at the forefront of oncology practice.

ACPS: an Accurate Bioinformatics Tool for Precision‐based Anti‐cancer Peptide Generation Via Omics Data

An Accurate Bioinformatics Tool For Anti-Cancer Peptide Generation Through Deep Learning Omics

A-CaMP: a Tool for Anti-Cancer and Antimicrobial Peptide Generation.

ANNprob-ACPs: A novel anticancer peptide identifier based on probabilistic feature fusion approach

Iacp: a Sequence-Based Tool for Identifying Anticancer Peptides.

Large-scale comparative review and assessment of computational methods for anti-cancer peptide identification

Effective identification and differential analysis of anticancer peptides

Precision Oncology and AI: the ACMA System for Personalized Treatment Matching Using Real-World Data.

Efficient Screening of Pharmacological Broad-Spectrum Anti-Cancer Peptides Utilizing Advanced Bidirectional Encoder Representation from Transformers Strategy

To Assist Oncologists: An Efficient Machine Learning-Based Approach for Anti-Cancer Peptides Classification

Computational design of anti-cancer peptides tailored to target specific tumor markers

Intelligent computational method for discrimination of anticancer peptides by incorporating sequential and evolutionary profiles information

ACP-CapsPred: an explainable computational framework for identification and functional prediction of anticancer peptides based on capsule network

Inacp: an Integrated Approach to the Prediction of Anticancer Peptides.

ACPScanner: Prediction of Anticancer Peptides by Integrated Machine Learning Methodologies

ACP-ML: A sequence-based method for anticancer peptide prediction

Extended dipeptide composition framework for accurate identification of anticancer peptides

LGBM-ACp: an ensemble model for anticancer peptide prediction and in silico screening with potential drug targets

An Integrated Tool for Multi-Dimensional Cancer Research Utilizing Clinical Proteomic Tumor Analysis Consortium Data

ACP-check: An anticancer peptide prediction model based on bidirectional long short-term memory and multi-features fusion strategy

Anti-Cancer Peptides Identification and Activity Type Classification with Protein Sequence Pre-training